Loading...
•
Sep 30, 2024
Phibro Q1 2025 Earnings Report
Reported strong first quarter results with significant growth in net sales and adjusted EBITDA.
Key Takeaways
Phibro Animal Health Corporation reported a strong first quarter with net sales increasing by 13% to $260.4 million and net income of $7.0 million. Adjusted EBITDA increased by 64% to $30.7 million, driven by strong performance in the Vaccines business and recovery in Mineral Nutrition and Performance Products. The company updated its fiscal year 2025 guidance, projecting net sales of $1.05 billion to $1.10 billion and adjusted EBITDA of $124 million to $132 million.
Net sales increased by 13% to $260.4 million.
Net income increased to $7.0 million, a $15.0 million increase.
Adjusted EBITDA increased by 64% to $30.7 million.
Updated fiscal year 2025 guidance projects net sales of $1.05 billion to $1.10 billion and adjusted EBITDA of $124 million to $132 million.
Revenue by Segment
Forward Guidance
Phibro has updated its fiscal year 2025 guidance, which includes net sales of $1.05 billion to $1.10 billion and adjusted EBITDA of $124 million to $132 million. This guidance is on a standalone basis without giving effect to the acquisition of Zoetis’ Medicated Feed Additive portfolio.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...